placebo delta 9 tetrahydrocannabinol

Preclinical

placebo delta 9 tetrahydrocannabinol is one of 5 therapeutic programs targeting Impairment. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

ImpairmentCompleted

ImpairmentPreclinical

Completed

Competition

Competitive Landscape

5 competitors in Impairment

#DrugCompanyPhaseTrials

LY3537031

Eli Lilly

Phase 1

1 2

Xe-133

NNobilis Therapeutics Inc.

Preclinical

1 3

Alcohol

Astellas

Preclinical

2 4

placebo delta 9 tetrahydrocannabinol

CCentre for Addiction and Mental Health

Preclinical

1 5

Delta-9-Tetrahydrocannabinol

CCentre for Addiction and Mental Health

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Impairment1 trial

Effects of Combined Alcohol and Cannabis on Young Drivers' Simulated Driving

Completed·CCentre for Addiction and Mental Health·Preclinical·NCT03106363·49 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for placebo delta 9 tetrahydrocannabinol. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for placebo delta 9 tetrahydrocannabinol. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Centre for Addiction and Mental Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: CCentre for Addiction and Mental Health

placebo delta 9 tetrahydrocannabinol

Status by Indication[2][1]

Competitive Landscape

Trials by Indication[1]

Impairment1 trial

References

Drug Info

Quick Facts

Related News